These are glimpses into the work we do, the things we care about, and the milestones we’re working towards.

2015 Financial Results

A strong 2015 saw our revenue grow 15 percent, delivering adjusted earnings-per-share of $4.29, up 29 percent from a year ago, and generating momentum we expect to build upon in 2016.

Remarkable 2015 for patients, top 5 reasons why

Our third year as AbbVie is drawing to a close. As we look back, it’s been an incredible year on many fronts, with successes in the laboratory, in manufacturing, in our commercial operations and behind the scenes, where our work to solidify our foundation as a stand-alone biopharmaceutical company has firmly taken root.

Spreading smart care across europe

Early intervention is one remedy for sustaining healthcare systems in Europe. The first installment of “Smart Care: Sustainable Health For The Future,” a new Euronews series, features our efforts to help Spanish patients with joint, muscle and back pain get back to work.

Well positioned for success: strong q3 results; top-tier growth through 2020

See AbbVie’s strong performance in Q3, with results well ahead of expectations, and the company’s long-term strategic and financial objectives, which provide guidance for total company sales of approximately $37 billion dollars in 2020.  

Second Quarter 2015 Financial Results

Our strong portfolio drove revenue growth in Q2 with adjusted EPS up 31.7 percent, while our strategic acquisition of Pharmacyclics and robust development pipeline position AbbVie well for the future.